Asset
PICLIDENOSON
Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00837291 | phase2 | withdrawn | 2018-11-01 | 2018-12-01 | Can-Fite BioPharma | A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee |
| NCT02647762 | phase3 | terminated | 2017-10-30 | 2020-11-30 | Can-Fite BioPharma | CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis |
| NCT03168256 | phase3 | completed | 2018-09-15 | 2022-01-06 | Can-Fite BioPharma | CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis |
| NCT01034306 | phase2 | completed | 2010-10-01 | 2013-12-01 | Can-Fite BioPharma | Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis |
| NCT00556894 | phase2 | completed | 2008-02-01 | 2009-03-01 | Can-Fite BioPharma | Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients |
FDA applications (0)
This company has no applications containing this asset.